Stay updated on Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A new page revision tag, v3.6.3, has been added to the study page, replacing the previous v3.6.2 tag. This represents an update to the page's versioning, indicating a newer revision of the study record.
    Difference
    0.0%
    Check dated 2026-07-03T22:41:35.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision: v3.6.2 replaces v3.6.0 on the page, indicating a backend software update; no visible content changes are implied by this revision tag.
    Difference
    0.0%
    Check dated 2026-06-26T20:51:49.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The SOPHIA study page now indicates that it is no longer recruiting participants. Enrollment is closed.
    Difference
    0.2%
    Check dated 2026-06-12T11:23:52.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The page's revision tag was updated to v3.5.5, replacing the former v3.5.4 tag to reflect a new version of the page.
    Difference
    0.0%
    Check dated 2026-06-05T08:27:02.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page revision number was updated from 3.5.3 to 3.5.4, indicating a new iteration of the record. This likely reflects minor edits or housekeeping rather than changes to study data or eligibility.
    Difference
    0.0%
    Check dated 2026-05-14T22:21:03.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The page’s locations list has a Denmark entry updated to use “Region Sjælland” instead of “Zeeland,” indicating a correction/standardization of regional naming. The revision label at the bottom is also updated, reflecting a site/version update rather than a substantive study change.
    Difference
    0.1%
    Check dated 2026-04-23T21:54:17.000Z thumbnail image

Stay in the know with updates to Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.